Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kehao Zhu

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Biostatistics & Epidemiology|October 26, 2019
Tree-based Ensemble Methods For Individualized Treatment RulesKehao Zhu, Ying Huang, Xiao-Hua Zhou
Biometrics|September 20, 2024
Designing cancer screening trials for reduction in late-stage cancer incidenceKehao Zhu, Ying-Qi Zhao, Yingye Zheng
Statistics in Biosciences|October 17, 2025
Weighted Brier Score - an Overall Summary Measure for Risk Prediction Models with Clinical Utility ConsiderationKehao Zhu, Yingye Zheng, Kwun Chuen Gary Chan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate UseKathleen F Kerr, Marshall D Brown, Kehao Zhu, et al.
Statistics in Medicine|April 2, 2026
Two-Step Error-Controlling Classifiers With Application to Cost-Effective Disease DiagnosisKehao Zhu, Kwun Chuen Gary Chan, Ying-Qi Zhao, et al.
Inflammatory Bowel Diseases|April 9, 2016
Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel DiseaseAnita Afzali, Christopher J Park, Kehao Zhu, et al.
Clinical Trials (London, England)|August 11, 2017
Evaluating biomarkers for prognostic enrichment of clinical trialsKathleen F Kerr, Jeremy Roth, Kehao Zhu, et al.
Journal of the National Cancer Institute|November 20, 2024
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabelingYibai Zhao, Roman Gulati, Zhenwei Yang, et al.
JAMA Oncology|August 28, 2020
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityMatthew R Cooperberg, Yingye Zheng, Anna V Faino, et al.
Urology Practice|May 5, 2023
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS CohortAdrian J Waisman Malaret, Peter Chang, Lisa Newcomb, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Biostatistics & Epidemiology|October 26, 2019
Tree-based Ensemble Methods For Individualized Treatment RulesKehao Zhu, Ying Huang, Xiao-Hua Zhou
Biometrics|September 20, 2024
Designing cancer screening trials for reduction in late-stage cancer incidenceKehao Zhu, Ying-Qi Zhao, Yingye Zheng
Statistics in Biosciences|October 17, 2025
Weighted Brier Score - an Overall Summary Measure for Risk Prediction Models with Clinical Utility ConsiderationKehao Zhu, Yingye Zheng, Kwun Chuen Gary Chan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate UseKathleen F Kerr, Marshall D Brown, Kehao Zhu, et al.
Statistics in Medicine|April 2, 2026
Two-Step Error-Controlling Classifiers With Application to Cost-Effective Disease DiagnosisKehao Zhu, Kwun Chuen Gary Chan, Ying-Qi Zhao, et al.
Inflammatory Bowel Diseases|April 9, 2016
Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel DiseaseAnita Afzali, Christopher J Park, Kehao Zhu, et al.
Clinical Trials (London, England)|August 11, 2017
Evaluating biomarkers for prognostic enrichment of clinical trialsKathleen F Kerr, Jeremy Roth, Kehao Zhu, et al.
Journal of the National Cancer Institute|November 20, 2024
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabelingYibai Zhao, Roman Gulati, Zhenwei Yang, et al.
JAMA Oncology|August 28, 2020
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityMatthew R Cooperberg, Yingye Zheng, Anna V Faino, et al.
Urology Practice|May 5, 2023
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS CohortAdrian J Waisman Malaret, Peter Chang, Lisa Newcomb, et al.
Pageof 2